Thank you
for joining us.

Patented CB-CAPs Biomarkers

Exclusively available through AVISE, our proprietary Cell-Bound Complement Activation Products (CB-CAPs) provide unprecedented insights and 22% greater sensitivity over traditional laboratory testing.

Discover new research as presented at ACR Convergence 2021!

We are thankful to all of the partners on this year’s presentations!

For more information on the new research, visit ACR’s Virtual Poster Hall, and view the abstracts:
#0325, #0868, #0877, #1086, #1764, #0003, #0010 and #0336.

The posters will remain in the Digital Poster Hall until December 31st, 2021.

Exagen Abstracts Overview

Poster Presentation | Presented by Roberta Alexander, PharmD, PhD | Abstract #0325
Title: A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus
Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323-0356)
Session Time: 8:30am – 10:30am EST

Poster Presentation | Presented by Richard Ramonell, MD | Abstract #0003
Title: Clinically Identifiable Autoreactivity is Common in Severe SARS- CoV-2 Infection
Session Title: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
Session Time: 8:30am – 10:30am EST

Poster Presentation | Presented by Matthew Woodruff, PhD | Abstract #0010
Title: Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19
Session Title: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
Session Time: 8:30am – 10:30am EST

Poster Presentation | Presented by Tyler O’Malley | Abstract #0336
Title: The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products Versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE
Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323-0356)
Session Time: 8:30am – 10:30am EST

Poster Presentation | Presented by Jennifer Rogers, MD | Abstract #0868
Title: Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity
Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Diagnosis (0855-0896)
Session Time: 8:30am – 10:30am EST

Poster Presentation | Presented by Kai Sun, MD | Abstract #0877
Title: Association of HCQ Blood Levels with Type 1 and 2 SLE Activity
Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Diagnosis (0855-0896)
Session Time: 8:30am – 10:30am EST

Poster Presentation | Presented by Mark Rudolph, PhD | Abstract #1086
Title: Lack of Effect of SARS-CoV-2 Vaccination on Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm and Inflammatory Biomarkers
Session Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083-1117)
Session Time: 8:30am – 10:30am EST

Poster Presentation | Presented by Kelley Brady | Abstract #1764
Title: Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients
Session Title: SLE – Treatment Poster (1732-1772)
Session Time: 8:30am – 10:30am EST